Longevity eye cream
US-2024423898-A1 · Dec 26, 2024 · US
US2025381131A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025381131-A1 |
| Application number | US-202319108546-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 31, 2023 |
| Priority date | Sep 5, 2022 |
| Publication date | Dec 18, 2025 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A composition for administration to a subject is disclosed. The composition comprises at least one botanical active component. The botanical active component is present in the composition in an amount effective to inhibit elastase activity in the skin of the subject. The botanical active component comprises at least one extract selected from the group consisting of: i) an extract of Potentilla glabra leaf; ii) an extract of Bombax malabaricum flower; iii) an extract of Amomum villosum seed; iv) an extract of Amomum kravanh fruit; v) an extract of Cornus officinalis fruit; and vi) combinations of i) to v). The composition may be in the form of a topical composition, e.g., for topical application. The composition may also be in the form of an oral composition, e.g., for ingestion. A method of inhibiting elastase activity in the skin of a subject is also provided. The method comprises administering an effective amount of the composition to the subject.
Opening claim text (preview).
1 . A composition for administration to a subject, the composition comprising at least one botanical active component, wherein the botanical active component comprises at least one extract selected from the group consisting of: i) an extract of Potentilla glabra leaf; ii) an extract of Bombax malabaricum flower; iii) an extract of Amomum villosum seed; iv) an extract of Amomum kravanh fruit; v) an extract of Cornus officinalis fruit; and vi) combinations of i) to v); wherein the botanical active component is present in the composition in an amount effective to inhibit elastase activity in skin of the subject. 2 . The composition according to claim 1 , wherein the botanical active component comprises the extract of Potentilla glabra leaf, optionally wherein the botanical active component consists of the extract of Potentilla glabra leaf. 3 . The composition according to claim 1 , wherein the extract of Potentilla glabra leaf is obtained by alcohol extracting, optionally ethanol extracting, leaves or leaf-based plant material of Potentilla glabra. 4 . The composition according to claim 1 , wherein the composition is substantially to completely free of components obtained from non-leaf-based plant material of Potentilla glabra. 5 . The composition according to claim 1 , wherein the botanical active component comprises the extract of Bombax malabaricum flower, optionally wherein the botanical active component consists of the extract of Bombax malabaricum flower. 6 . The composition according to claim 1 , wherein the extract of Bombax malabaricum flower is obtained by alcohol extracting, optionally ethanol extracting, flowers or flower-based plant material of Bombax malabaricum. 7 . The composition according to claim 1 , wherein the composition is substantially to completely free of components obtained from non-flower-based plant material of Bombax malabaricum. 8 . The composition according to claim 1 , wherein the botanical active component comprises the extract of Amomum villosum seed, optionally wherein the botanical active component consists of the extract of Amomum villosum seed. 9 . The composition according to claim 1 , wherein the extract of Amomum villosum seed is obtained by alcohol extracting, optionally ethanol extracting, seeds or seed-based plant material of Amomum villosum. 10 . The composition according to claim 1 , wherein the composition is substantially to completely free of components obtained from non-seed-based plant material of Amomum villosum. 11 . The composition according to claim 1 , wherein the botanical active component comprises the extract of Amomum kravanh fruit, optionally wherein the botanical active component consists of the extract of Amomum kravanh fruit. 12 . The composition according to claim 1 , wherein the extract of Amomum kravanh fruit is obtained by alcohol extracting, optionally ethanol extracting, fruit or fruit-based plant material of Amomum kravanh. 13 . The composition according to claim 1 , wherein the composition is substantially to completely free of components obtained from non-fruit-based plant material of Amomum kravanh. 14 . The composition according to claim 1 , wherein the botanical active component comprises the extract of Cornus officinalis fruit, optionally wherein the extract of Cornus officinalis is further defined as an extract of Cornus officinalis fruit. 15 . The composition according to claim 1 , wherein the extract of Cornus officinalis fruit is obtained by water extracting (or aqueous extracting) fruit or fruit-based plant material of Cornus officinalis. 16 . The composition according to claim 1 , wherein the extract of Cornus officinalis fruit is obtained by alcohol extracting, optionally ethanol extracting, fruit or fruit-based plant material of Cornus officinalis. 17 . The composition according to claim 1 , wherein the composition is substantially to completely free of components obtained from non-fruit-based plant material of Cornus officinalis. 18 . The composition according to claim 1 , wherein the composition is further defined as a topical composition that is formulated for topical administration to the subject. 19 . The composition according to claim 18 , further comprising a cosmetically acceptable carrier, optionally wherein the cosmetically acceptable carrier is not naturally occurring. 20 . (canceled) 21 . A method of inhibiting elastase activity in skin of a subject, the method comprising administering, optionally topically administering, an effective amount of a composition to the subject, wherein the composition is according to claim 1 . 22 . (canceled)
Anti-ageing preparations · CPC title
Liliopsida [monocotyledons] · CPC title
Malvaceae (Mallow family) · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Plant extracts · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.